Compass Pathways Plc
$ 6.73
0.75%
29 Dec - close price
- Market Cap 646,195,000 USD
- Current Price $ 6.73
- High / Low $ 6.79 / 6.56
- Stock P/E N/A
- Book Value 0.39
- EPS -2.72
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.38 %
- ROE -2.06 %
- 52 Week High 7.15
- 52 Week Low 2.25
About
Compass Pathways plc is a leading mental health care innovator dedicated to creating groundbreaking psychedelic therapies, primarily utilizing psilocybin, to tackle pressing unmet needs in mental health treatment. Based in Cheshire, UK, the company actively engages in clinical research across the UK and US, with a primary focus on addressing treatment-resistant depression. Through its steadfast commitment to research and development, Compass Pathways aims to set new benchmarks in mental health care and expand therapeutic alternatives, ultimately striving to enhance patient outcomes on a global scale.
Analyst Target Price
$16.82
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-30 | 2025-07-30 | 2025-05-06 | 2025-02-26 | 2024-10-31 | 2024-08-01 | 2024-05-08 | 2024-02-29 | 2023-11-02 | 2023-08-03 | 2023-05-11 | 2023-02-28 |
| Reported EPS | -0.3836 | -0.4114 | -0.4185 | -0.63 | -0.56 | -0.56 | -0.55 | -0.53 | -0.67 | -0.62 | -0.57 | -0.73 |
| Estimated EPS | -0.3955 | -0.4228 | -0.49 | -0.63 | -0.57 | -0.52 | -0.49 | -0.33 | -0.43 | -0.69 | -0.68 | -0.59 |
| Surprise | 0.0119 | 0.0114 | 0.0715 | 0 | 0.01 | -0.04 | -0.06 | -0.2 | -0.24 | 0.07 | 0.11 | -0.14 |
| Surprise Percentage | 3.0088% | 2.6963% | 14.5918% | 0% | 1.7544% | -7.6923% | -12.2449% | -60.6061% | -55.814% | 10.1449% | 16.1765% | -23.7288% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CMPS
2025-12-27 07:43:00
COMPASS Pathways plc (NASDAQ:CMPS) is gathering attention, with analysts maintaining a "Buy" or equivalent rating and a median price target of $15, implying significant upside potential. Oppenheimer recently upgraded CMPS to Outperform, citing prospects for its psilocybin therapy (COMP360) for treatment-resistant depression, forecasting nearly $1.5 billion in sales. The company is poised to advance through upcoming catalysts with a strong financial footing and an early-mover advantage in the psychedelics space.
2025-12-24 14:52:00
The psychedelic drug market is experiencing a significant shift, moving from the fringes to the mainstream with increasing regulatory support and political backing from figures like Robert F. Kennedy Jr. Two companies, Compass Pathways and Mind Medicine, are leading this charge, both positioned to address a massive unmet need in mental health. While Mind Medicine shows strong retail sentiment and a longer cash runway, Compass Pathways' lead candidate, COMP360, may reach the market sooner, intensifying the competition in this rapidly growing sector.
2025-12-24 12:13:44
COMPASS Pathways (NASDAQ:CMPS) recently hit a new 52-week high of $7.15 on heavy trading volume, reflecting significant upward momentum with its stock trading above key moving averages. This comes amidst positive analyst sentiment, including upgraded ratings and a "Moderate Buy" consensus, driven by its clinical-stage psilocybin therapy for treatment-resistant depression. Despite current unprofitability, the company's progress with its COMP360 program and Breakthrough Therapy designation contributes to investor optimism.
2025-12-13 16:08:35
COMPASS Pathways (NASDAQ:CMPS) hit a new 52-week high of $7.11 on Friday, with the stock closing at $7.0650. This comes as analysts have a "Moderate Buy" consensus rating and a target price of $15.88, despite one firm maintaining a "sell" rating. The company is advancing its COMP360 psilocybin therapy through Phase III trials for treatment-resistant depression.
2025-12-10 12:09:23
Compass Pathways plc (Nasdaq: CMPS) will host a webinar on January 7, 2026, at 10:00 am ET, focusing on its commercial preparations for treatment-resistant depression (TRD) and clinical trial plans for post-traumatic stress disorder (PTSD). Key opinion leaders and industry experts will discuss the current treatment landscape and unmet needs in TRD and PTSD, including patient care pathways and provider economics for multi-hour treatments. The company's management will also review commercial readiness for COMP360 in TRD and detail the planned late-stage program for COMP360 in PTSD.
2025-12-10 04:09:26
Biotech stocks experienced significant after-hours rallies driven by new clinical data, FDA designations, and financing news. Stoke Therapeutics, Alpha Tau Medical, and Compass Pathways were among the leaders, with several companies rebounding from earlier session losses. These movements highlight key catalysts that are influencing investor interest in the biotech sector.
